Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Sultzer

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|February 7, 2017
Cholinergic Receptor Binding in Alzheimer Disease and Healthy Aging: Assessment In Vivo with Positron Emission Tomography ImagingDavid L Sultzer, Rebecca J Melrose, Hannah Riskin-Jones, et al.
The New England Journal of Medicine|October 19, 2012
Relapse risk after discontinuation of risperidone in Alzheimer's diseaseD P Devanand, Jacobo Mintzer, Susan K Schultz, et al.
The American Journal of Psychiatry|June 4, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trialDavid L Sultzer, Sonia M Davis, Pierre N Tariot, et al.
The American Journal of Psychiatry|April 17, 2009
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD studyLing Zheng, Wendy J Mack, Karen S Dagerman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 9, 2025
Neuropsychiatric symptoms and emerging dementia in people with Down syndrome and older adultsChristina M Magana-Ramirez, Daniel L Gillen, Christy L Hom, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Clinical ManifestationsChristina M Magana-Ramirez, Daniel L Gillen, Christy L Hom, et al.
The New England Journal of Medicine|July 21, 2021
Trial of Pimavanserin in Dementia-Related PsychosisPierre N Tariot, Jeffrey L Cummings, Maria E Soto-Martin, et al.
The American Journal of Psychiatry|November 19, 2016
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of HallucinationsAnjali N Patel, Seonjoo Lee, Howard F Andrews, et al.
Journal of Psychiatric Research|May 11, 2024
Deep brain stimulation of the amygdala for treatment-resistant combat post-traumatic stress disorder: Long-term resultsRalph J Koek, Josue Avecillas-Chasin, Scott E Krahl, et al.
The New England Journal of Medicine|October 13, 2006
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's diseaseLon S Schneider, Pierre N Tariot, Karen S Dagerman, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|February 7, 2017
Cholinergic Receptor Binding in Alzheimer Disease and Healthy Aging: Assessment In Vivo with Positron Emission Tomography ImagingDavid L Sultzer, Rebecca J Melrose, Hannah Riskin-Jones, et al.
The New England Journal of Medicine|October 19, 2012
Relapse risk after discontinuation of risperidone in Alzheimer's diseaseD P Devanand, Jacobo Mintzer, Susan K Schultz, et al.
The American Journal of Psychiatry|June 4, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trialDavid L Sultzer, Sonia M Davis, Pierre N Tariot, et al.
The American Journal of Psychiatry|April 17, 2009
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD studyLing Zheng, Wendy J Mack, Karen S Dagerman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 9, 2025
Neuropsychiatric symptoms and emerging dementia in people with Down syndrome and older adultsChristina M Magana-Ramirez, Daniel L Gillen, Christy L Hom, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Clinical ManifestationsChristina M Magana-Ramirez, Daniel L Gillen, Christy L Hom, et al.
The New England Journal of Medicine|July 21, 2021
Trial of Pimavanserin in Dementia-Related PsychosisPierre N Tariot, Jeffrey L Cummings, Maria E Soto-Martin, et al.
The American Journal of Psychiatry|November 19, 2016
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of HallucinationsAnjali N Patel, Seonjoo Lee, Howard F Andrews, et al.
Journal of Psychiatric Research|May 11, 2024
Deep brain stimulation of the amygdala for treatment-resistant combat post-traumatic stress disorder: Long-term resultsRalph J Koek, Josue Avecillas-Chasin, Scott E Krahl, et al.
The New England Journal of Medicine|October 13, 2006
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's diseaseLon S Schneider, Pierre N Tariot, Karen S Dagerman, et al.
Pageof 7